Trial Profile

SAINT: A Phase 1/2 Study of Safe Amounts of IPLIMUMAB, NIVOLUMAB and TRABECTEDIN for Previously Treated Advanced Soft Tissue Sarcoma (STS)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 28 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Trabectedin (Primary)
Indications Chondrosarcoma; Clear cell sarcoma; Endometrial cancer; Leiomyosarcoma; Malignant fibrous histiocytoma; Soft tissue sarcoma; Synovial sarcoma
Focus Adverse reactions
Acronyms SAINT

Most Recent Events

24 Feb 2025 Planned number of patients changed from 45 to 250.
24 Feb 2025 Planned End Date changed from 31 Mar 2025 to 31 Jul 2031.
24 Feb 2025 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2030.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com